This digital document is a journal article from Addictive Behaviors, published by Elsevier in 2005. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.

Description:
Background: Based on pre-clinical studies regarding the interaction of various antidepressant drugs with the opioid system, we designed a clinical study to be carried out in the 'in-patient detoxification unit' within a large community centre for treatment of drugs dependent people. We evaluated the effect of mianserin add-on, on the intensity of opioid withdrawal symptoms in opiate dependent subjects undergoing medication-supported physical detoxification and integrated psychosocial and psychotherapeutic intervention for the treatment of dependence. Methods: Mianserin (or placebo) was added to the routine medication protocol, during the 3-week in-patient phase of detoxification in a prospective, randomized, double blind, placebo controlled study. Mianserin (or placebo) was continued after discharge and patients were followed up for 3 months in order to evaluate relapse rates. Opiate withdrawal symptoms were assessed during the first 10 days, while depression and anxiety were assessed throughout the 3 months of study. Results: From day 2 onward, patients in the study group showed significantly lower withdrawal symptoms than the control group patients and reached this peak faster (study group 2.8 days, control group 3.2 days, p

In Buprenorphine Therapy of Opiate Addiction, participating physicians and toxicologists summarize and evaluate their experiences with five years of intensive buprenorphine therapy. They cover all aspects of its use, including the pharmacology, conditions of delivery, risks from use with other psychoactive drugs, toxicology and related deaths, as well as its testing in blood, urine, tissue, and hair. Special attention is given to comparing the long-term care of opiate-dependent patients using high-dose buprenorphine vs methadone, and to explaining the differences in treatment, administration, and delivery. The authors also describe how buprenorphine is currently prescribed and monitored in France and Australia, and review all the latest advances in analytical techniques for the determination of buprenorphine and its metabolites in biological fluids and tissues.

Hardcover: 148 pages
Company: Humana Press (2002-02-15)
ISBN: 158829031X
List Price: $115.00
Amazon Price: $36.18
Used Price: $57.00

Abstract: Objective To assess the efficacy and safety of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®; MS-sNT), which contain morphine sulfate pellets with a sequestered naltrexone core, in treating patients with chronic, moderate-to-severe osteoarthritis (hip or knee) pain. Patients and Methods This phase 3 study had an enriched-enrollment, randomized-withdrawal, double-blind, multicenter design. Patients (N = 547) were titrated to an effective dose of MS-sNT (20–160 mg/day). Responders (n = 344) were randomized to 12 weeks maintenance with an effective MS-sNT dose or were tapered to placebo over 2 weeks. The primary efficacy measure was the change from baseline (CFB) in diary average-pain scores (0–10 scale, Brief Pain Inventory [BPI]) from randomization to the last 7 days of the maintenance period. Secondary efficacy measures included the remaining BPI scores and Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index. Opioid withdrawal symptoms were assessed by the Clinical Opiate Withdrawal Scale (COWS) and Subjective Opiate Withdrawal Scale (SOWS). The study ran from January 10, 2007 through November 8, 2007. Results MS-sNT maintained pain control better than placebo (mean CFB, diary average-pain score, −0.2 ± 1.9 vs ±0.3 ± 2.1; P = 0.045). Change from baseline for MS-sNT pain-diary score (worst, least, average, current) was superior during the maintenance period visits, weeks 2 to 12 (P < 0.05). WOMAC composite score CFB was superior at most visits. MS-sNT was generally well tolerated, with a typical morphine safety profile. No patient taking MS-sNT as directed experienced withdrawal symptoms. Conclusion MS-sNT provided effective analgesia in patients with chronic, moderate-to-severe osteoarthritis pain, with a safety profile typical of morphine-containing products. Naltrexone sequestered in MS-sNT had no clinically relevant effect when MS-sNT was taken as directed.

Original Publication Date: July 2010

Author: Nathaniel Katz, David Morris, Martin Hale, Joseph Stauffer
Kindle Edition: Kindle eBook
Company: JTE Multimedia (2011-04-20) (2011-04-20)
List Price: $9.99
Amazon Price:

This digital document is an article from Internal Medicine News, published by International Medical News Group on May 1, 2004. The length of the article is 7603 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Pain rehabilitation program: opioid withdrawal helps chronic pain patients.(Clinical Rounds)
Author: Steve Perlstein
Publication: Internal Medicine News (Magazine/Journal)
Date: May 1, 2004
Publisher: International Medical News Group
Volume: 37 Issue: 9 Page: 27(1)

Distributed by Thomson Gale

Author: Steve Perlstein
Digital: 26 pages HTML
Company: International Medical News Group (2004-05-01) (2005-06-01)
List Price: $5.95
Amazon Price: $5.95

This digital document is a journal article from Addictive Behaviors, published by Elsevier in 2006. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.

Description:
There is a growing interest in the development of new pharmacological tools for treating alcohol withdrawal and dependence. A number of anticonvulsants including valproate and carbamazepine have been shown to be safe and effective alternatives to benzodiazepines for treating alcohol withdrawal. These agents are relatively safe, are free from demonstrated abuse liability, and do not usually potentiate the psychomotor and cognitive effects of alcohol. For the treatment of alcohol dependence, there is a growing literature on the utility of medications that have neurochemical effects at opioid, serotonergic, GABAergic, and glutamate receptors. Furthermore, as a class of medication, there appears to be a growing interest in investigating the utility of novel anticonvulsants such as topiramate for the treatment of alcohol dependence.

Author: N. Ait-Daoud, R.J. Malcolm, B.A. Johnson
Digital: 21 pages HTML
Company: Elsevier (2006-09-01)
List Price: $7.95
Amazon Price: $7.95

Some general aspects of opiate dependence are described in a first section including a brief historical description and an explanation of the different models currently used to investigate opiate dependence. The neurobiological bases of opiate withdrawal are detailed in a second section, which particularly emphasizes the neurophysiological adaptative changes, the processes of homologous and heterologous regulation, and the role played by different brain structures and several endogenous peptides acting as antiopiates. The last part reports several basic aspects more directly related to the clinical perspectives of opiate dependence, such as the new expectations in the treatment of opiate withdrawal or the relationships between sensitization, tolerance and withdrawal.

Author: Rafael Maldonado, Luis Stinus, George F. Koob
Hardcover: 204 pages
Company: R G Landes Co (1996-06)
ISBN: 1570593477
List Price: $139.00
Amazon Price: $101.47
Used Price: $55.00

This second edition of the “Encyclopedia of Drugs, Alcohol, and Addictive Behavior” reflects changes in the attitudes about, use, and knowledge of drugs and alcohol since the first edition published in 1995. These changes include the decrease of crack cocaine use and resurgence of heroin use; changes in laws dealing with drug use (on both the state and national levels), and new discoveries leading to a better understanding of how drugs work and what makes them addictive. More than 700 articles, written for both the student and layperson, cover the social, medical and political issues related to drugs and alcohol, as well exploring and explaining types of addiction.

Author: JAMES F. MADDUX, DAVID P. DESMOND
Digital: 6 pages HTML
Company: Macmillan Reference USA (2001)
List Price: $3.95
Amazon Price: $3.95

This second edition of the “Encyclopedia of Drugs, Alcohol, and Addictive Behavior” reflects changes in the attitudes about, use, and knowledge of drugs and alcohol since the first edition published in 1995. These changes include the decrease of crack cocaine use and resurgence of heroin use; changes in laws dealing with drug use (on both the state and national levels), and new discoveries leading to a better understanding of how drugs work and what makes them addictive. More than 700 articles, written for both the student and layperson, cover the social, medical and political issues related to drugs and alcohol, as well exploring and explaining types of addiction.

Author: WILLIAM R. MARTIN, REBECCA J. FREY, REBECCA MARLOW-FERGUSON
Digital: 7 pages HTML
Company: Macmillan Reference USA (2001)
List Price: $3.95
Amazon Price: $3.95

The successor to Strain and Stitzer's Methadone Treatment for Opioid Dependence (Johns Hopkins, 1999), this expanded and updated volume reflects new developments in treatment protocols.

Methadone is still the most widely used medication for the treatment of opioid dependence, and the authors provide an extensive section on methadone treatment. Three chapters cover the pharmacology and clinical use of buprenorphine as well as the latest research on Naltrexone, Clonidine, and Lofexidine. The volume also includes chapters on pain and prescription opioids as well as medication-free treatment and medically supervised alternatives to opioid substitute treatments, including withdrawal.

The Treatment of Opioid Dependence will be a valuable resource for methadone counselors, psychiatrists, psychologists, social workers, mental health nurses, and addiction counselors, as well as physicians interested in office-based buprenorphine treatment.

Hardcover: 576 pages
Company: The Johns Hopkins University Press (2005-11-08)
ISBN: 0801882192
List Price: $65.00
Amazon Price: $33.66
Used Price: $33.55

This digital document is an article from Clinical Psychiatry News, published by International Medical News Group on May 1, 2004. The length of the article is 8011 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Opioid withdrawal plan may help chronic pain patients.(Pain Medicine)
Author: Steve Perlstein
Publication: Clinical Psychiatry News (Magazine/Journal)
Date: May 1, 2004
Publisher: International Medical News Group
Volume: 32 Issue: 5 Page: 76(1)

Distributed by Thomson Gale

Author: Steve Perlstein
Digital: 27 pages HTML
Company: International Medical News Group (2004-05-01) (2005-06-01)
List Price: $5.95
Amazon Price: $5.95